Apnimed's sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date
Apnimed says its new drug application for AD109 (proposed name Oxnimbi) in adult obstructive sleep apnoea remains under FDA review, as it reports a Q3 net loss of $29.5m.
Apnimed said on 16 November 2026 that the US Food and Drug Administration is still reviewing its new drug application for AD109, a combination of aroxybutynin and atomoxetine proposed for adults with obstructive sleep apnoea. The proposed brand name is Oxnimbi. The agency's PDUFA goal date is 28 February 2027.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Apnimed, Inc. ↗
Article written by VigiEye from the official source (Apnimed, Inc.). Claims are the company's own. AI-assisted; check the source before acting.